Genewiz, Azenta Life Sciences’ genomics services provider, launched Gene Synthesis 2.0, an updated platform designed to simplify how researchers design and order genes.
Built around three packages, Sprint, Flex, and Flex+, Gene Synthesis 2.0 introduces a streamlined, intuitive ordering experience, according to Trey Martin, president of Genewiz, who adds that researchers can design cloning strategies, select vectors, assess sequence complexity, and place orders in minutes.
The product also introduces an upgraded codon optimization capability that combines established heuristic approaches with machine‑learning models trained on a high‑expression dataset, continues Martin. This approach can improve expression reliability across a wide range of organisms and sequence architectures while maintaining customer control over design choices, he points out.
“Gene Synthesis 2.0 reflects how researchers work today—where speed, clarity, and reliability matter at every step,” says Martin, “By simplifying the path from sequence design to execution, this offering helps scientists move faster in rapidly evolving fields such as antibody discovery, AI-enabled biology, and gene and cell therapy.”
Gene Synthesis 2.0 is being highlighted at ASGCT this week at booth 915.
